To compare the efficacy and the period of use of tocilizumab and infliximab during treatment of rheumatoid arthritis patients.
The period of use of two biologics with different mechanisms of action were compared in treatment of rheumatoid arthritis patients.
Both medications showed efficacy, but the period of use with no loss of efficacy was longer in patients receiving tocilizumab when compared to infliximab.
Tocilizumab maintains a period of use significantly longer as compared with infliximab in patients with rheumatoid arthritis treated at a single organization.